These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29955475)

  • 21. Impulsive and compulsive behaviors during dopamine replacement treatment in Parkinson's Disease and other disorders.
    Raja M; Bentivoglio AR
    Curr Drug Saf; 2012 Feb; 7(1):63-75. PubMed ID: 22663960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience.
    Limotai N; Oyama G; Go C; Bernal O; Ong T; Moum SJ; Bhidayasiri R; Foote KD; Bowers D; Ward H; Okun MS
    Int J Neurosci; 2012 Mar; 122(3):145-53. PubMed ID: 22023411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infusion Therapies and Development of Impulse Control Disorders in Advanced Parkinson Disease: Clinical Experience After 3 Years' Follow-up.
    Todorova A; Samuel M; Brown RG; Chaudhuri KR
    Clin Neuropharmacol; 2015; 38(4):132-4. PubMed ID: 26166238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine agonist withdrawal syndrome: A comprehensive review.
    Yu XX; Fernandez HH
    J Neurol Sci; 2017 Mar; 374():53-55. PubMed ID: 28104232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long term follow-up of Parkinson's disease patients with impulse control disorders.
    Sohtaoğlu M; Demiray DY; Kenangil G; Ozekmekçi S; Erginöz E
    Parkinsonism Relat Disord; 2010 Jun; 16(5):334-7. PubMed ID: 20223696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease.
    Weiss HD; Marsh L
    Neurol Clin Pract; 2012 Dec; 2(4):267-274. PubMed ID: 23634371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson disease treatment center.
    Patel S; Garcia X; Mohammad ME; Yu XX; Vlastaris K; O'Donnell K; Sutton K; Fernandez HH
    J Neurol Sci; 2017 Aug; 379():308-311. PubMed ID: 28716269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopamine agonist withdrawal syndrome associated factors: A retrospective chart review.
    Garcia X; Mohammad ME; Patel S; Yu XX; Fernandez HH
    Clin Park Relat Disord; 2022; 7():100153. PubMed ID: 35909701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine agonist withdrawal syndrome in Parkinson disease.
    Rabinak CA; Nirenberg MJ
    Arch Neurol; 2010 Jan; 67(1):58-63. PubMed ID: 20065130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
    Solla P; Fasano A; Cannas A; Mulas CS; Marrosu MG; Lang AE; Marrosu F
    Parkinsonism Relat Disord; 2015 Aug; 21(8):968-71. PubMed ID: 26071817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trait Impulsivity and Anhedonia: Two Gateways for the Development of Impulse Control Disorders in Parkinson's Disease?
    Houeto JL; Magnard R; Dalley JW; Belin D; Carnicella S
    Front Psychiatry; 2016; 7():91. PubMed ID: 27303314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impulse control disorders in Parkinson's disease: Review of pathophysiology, epidemiology, clinical features, management, and future challenges.
    Bhattacharjee S
    Neurol India; 2018; 66(4):967-975. PubMed ID: 30038082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders.
    Ceravolo R; Frosini D; Rossi C; Bonuccelli U
    J Neurol; 2010 Nov; 257(Suppl 2):S276-83. PubMed ID: 21080189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A survey of impulse control disorders in Parkinson's disease patients in Shanghai area and literature review.
    Wang XP; Wei M; Xiao Q
    Transl Neurodegener; 2016; 5():4. PubMed ID: 26893825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management.
    Ceravolo R; Frosini D; Rossi C; Bonuccelli U
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S111-5. PubMed ID: 20123548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impulse control disorders in Parkinson's disease: prevalence and possible risk factors.
    Weintraub D
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S110-3. PubMed ID: 20082968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impulse Control Disorders in Parkinson's Disease. A Brief and Comprehensive Review.
    Gatto EM; Aldinio V
    Front Neurol; 2019; 10():351. PubMed ID: 31057473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study.
    Weintraub D; Sohr M; Potenza MN; Siderowf AD; Stacy M; Voon V; Whetteckey J; Wunderlich GR; Lang AE
    Ann Neurol; 2010 Dec; 68(6):963-8. PubMed ID: 21154480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial.
    Lee JY; Jeon B; Koh SB; Yoon WT; Lee HW; Kwon OD; Kim JW; Kim JM; Ma HI; Kim HT; Baik JS; Cho J;
    J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):30-37. PubMed ID: 30361296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathological gambling in Parkinson's disease. A comprehensive review.
    Santangelo G; Barone P; Trojano L; Vitale C
    Parkinsonism Relat Disord; 2013 Jul; 19(7):645-53. PubMed ID: 23490464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.